Company Liquidation PLC

Company profile

Destiny Pharma PLC

UK company 03167025, incorporated on 4 March 1996.

Destiny Pharma | World-leading infection prevention.

World-leading infection prevention.

Company number
03167025
Incorporated
4 Mar 1996
Companies House status
Liquidation

Company identity

Founded / incorporated
4 March 1996

Company number 03167025

Verify at Companies House
Legal name
DESTINY PHARMA LIMITED
Company type
Private Limited Company
Region
London
Registered address
C/O CORK GULLY LLP, 40
VILLIERS STREET
LONDON
WC2N 6NJ
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

Destiny Pharma PLC
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

5 events
30 Sep
2025

Accounts due

Accounts Due

Next accounts due date

22 Dec
2024

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2023

Accounts filed

Accounts

Last accounts made up date

08 Dec
2023

Confirmation statement filed

Confirmation

Last confirmation statement made up date

04 Mar
1996

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2019
Funded years
2019, 2020
Age at first award
22 years

Projects

2020 Collaborative R&D

SPOR-COV: Prophylaxis of COVID-19 using Innate Immunity

1 Sep 2020 to 31 Oct 2022

Awarded
£220,683
Total cost £315,900

The COVID-19 pandemic demonstrates the need for a rapid response to a global public health emergency. Vaccination is ideal but, as is now apparent, a vaccine for an unknown disease cannot be produced in time to avert a major socio-economic disaster. Alternative strategies have been considered but so far have received little attention. One of these is that...

2019 Collaborative R&D Lead participant

Evaluation of the Novel XF Drugs as Bacterial Resistance Breakers

1 Jan 2019 to 31 Aug 2022

Awarded
£362,389
Total cost £517,707

There is an urgent need for new drugs to treat infections resulting from bacteria that are now resistant to many of the current marketed antibiotics. This is a global issue encountered in low and middle-income countries (LMICs) where healthcare provisions may be less prevalent and so the impact is even greater. The jointly funded UK Department of Health a...

Product types

Collaborative R&D